Tweet
ThirdAge
<img alt="" height="1" width="1" />
Savient aims for primary care with new Krystexxa data
FiercePharma
Savient Pharmaceuticals ($SVNT) hasn't made huge inroads with its new gout drug, Krystexxa. Over the first 6 months of the year, the drug generated only $1.4 million in sales. But the company is now hoping some new study data will help jump-start its ...
Small-cap Analyst Biotech Pick; Savient gains on Positive Study ResultsBeacon Equity Research
Gout drug may help some with few treatment optionsReuters
Enzyme Works for Hard-to-Treat GoutMedPage Today
U.S. News & World Report -Bloomberg -Medscape
all 53 news articles »
More...